Management of hepatitis B virus reactivation during chemotherapy or immunosuppressive therapy

[Guest guest]

Presse Med. 2008 Jun 12. [Epub ahead of print]

[Management of hepatitis B virus reactivation during chemotherapy or

immunosuppressive therapy.]

[Article in French]

Amouri A, Chtourou L, Mnif L, Tahri N.

Service de gastro-entérologie, EPS Hédi Chaker – TN-3029 Sfax, Tunisie.

Reactivation of viral hepatitis B is a well-known complication in patients

receiving chemotherapy or immunosuppressive therapy; its incidence reaches 50%.

This reactivation is associated with a high rate of morbidity and mortality.

Prophylactic treatment of viral reactivation with lamivudine resulted in

lowering the incidence of this risk and improving prognosis in recent studies.

Patients with hematological malignancies and other cancers require a precise

assessment of their hepatitis B status and adequate management. There is not yet

a consensus about the appropriateness of prophylactic treatment of occult

hepatitis B infection or of pretreatment virologic assessment, especially

measurement of viral DNA.

PMID: 18555638 [PubMed - as supplied by publisher]

_________________________________________________________________

Introducing Live Search cashback . It's search that pays you back!

http://search.live.com/cashback/? & pkw=form=MIJAAF/publ=HMTGL/crea=introsrchcashb\

ack